Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
FSD Pharma Inc. HUGE
$1.10
+$0.01 (0.92%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
45520944.00000000
-
week52high
2.10
-
week52low
0.62
-
Revenue
0
-
P/E TTM
-7
-
Beta
0.90330300
-
EPS
-0.63000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:30
Описание компании
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
FSD Pharma says recruiting underway in Phase 2 Trial of FSD201 for treating chronic pain associated with idiopathic MCAS
Proactive Investors
30 янв 2023 г. в 09:09
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said recruiting is underway for the Phase 2 clinical trial of FSD-PEA (FSD201) for the treatment of chronic pain associated with idiopathic Mast Cell Activation Syndrome (MCAS) at two clinical sites in the US while a Canadian site is to be ready to recruit soon. The Toronto-based biopharmaceutical company said FSD201 is a proprietary anti-inflammatory compound with the potential to address a wide range of inflammatory diseases and associated conditions.
FSD Pharma submits clinical trial application for its multiple sclerosis treatment candidate Lucid-MS
Proactive Investors
17 янв 2023 г. в 10:12
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) announced it has submitted a Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS, a candidate for the treatment of multiple sclerosis (MS). In a statement, FSD Pharma called Lucid-MS a “first-in-class neuroprotective compound” with a novel mechanism action that has shown to prevent myelin degradation, which can cause MS and other neurodegenerative diseases.
FSD Pharma plans buyback of up to 1.9 million shares to utilize cash reserves
Proactive Investors
13 янв 2023 г. в 09:46
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up to 1.9 million of its subordinate Class B voting shares over the next 12 months. “FSD Pharma is focused on the advancement of its drug candidates toward the clinic, and we recognize there may be a strategic opportunity to enhance shareholder value without compromising our ambitious growth plans,” the company's interim CEO Anthony Durkacz said in a statement.
FSD Pharma incorporates new subsidiary to capitalize on drug development incentives in Australia
Proactive Investors
09 янв 2023 г. в 10:18
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The Toronto-based biopharma firm told investors it has also appointed a number of new doctors to its Scientific and Clinical Expert Committee and is investigating other products addressing acute medical needs due to substances of abuse such as alcohol.
FSD Pharma announces changes to its board of directors
Proactive Investors
29 ноя 2022 г. в 07:18
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the appointments of Dr Lakshmi P. Kotra and Joseph L.